A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors
Woo SB, Schacterle RS, Komaroff AL, Gallagher GT
While it has been studied for decades, it has never advanced into full pharmaceutical approval
The shRNA constructs against NRF2 were designed targeting guggcugcucagaauugcaga (sh NRF2 -1), guaagaagccagauguuaaga (sh NRF2 -2), and gcuccuacugugaugugaaau (sh NRF2 -3) (#230086 and 230087, Addgene)
A sublingual form that easily absorbs into the bloodstream and avoids the oxidative conditions of the digestive tract is an intriguing way to achieve that, and it may yield incredibly positive results in future research and practice